Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TW001
- Development stage
- Phase 2
- Lead developer
- Treeway
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TW001 is an oral formulation of edaravone, a small molecule free radical scavenger developed by Treeway B.V. for the treatment of Alzheimer's disease. It functions by donating electrons to free radical products, thereby reducing oxidative and nitrosative stress, which are key contributors to neurodegeneration. The drug is currently being evaluated in the Phase 2a ASURE trial for safety, pharmacokinetics, and pharmacodynamics in patients with mild-to-moderate Alzheimer's disease. While edaravone is already approved for amyotrophic lateral sclerosis (ALS) under the trade name Radicava, TW001 represents a specific development effort for the Alzheimer's population.
- Other names
- edaravoneoral edaravone
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on TW001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TW001.